SCHEMBL1714760

SCHEMBL1714760

COc1ccc(CONC(=O)c2cccnc2NCc2ccccc2Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.56
MEN1 O00255 6/20 0.48
KMT2A Q03164 6/20 0.48
MAPT P10636 4/20 0.48
ALDH1A1 P00352 4/20 0.47
RAB9A P51151 2/20 0.47
NPC1 O15118 2/20 0.47
TOP1 P11387 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
MAPK1 P28482 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
GAA P10253 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
KDR P35968 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1714828 0.90 NPC1 (0.50) MAPK8MEN1KMT2AMAPTRAB9A
SCHEMBL1715425 0.89 MAPT (0.49) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL1715449 0.88 MEN1 (0.54) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL1714982 0.87 MEN1 (0.60) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL1715544 0.87 MEN1 (0.60) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL1715137 0.85 MEN1 (0.47) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL1714581 0.83 PDPK1 (0.52) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL1716082 0.82 NPC1 (0.57) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL1715625 0.80 NPC1 (0.60) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL1714806 0.79 KDR (0.58) MEN1KMT2AMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US claimed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP claimed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US claimed
JP-2007513098-A 2007-05-24 JP claimed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO claimed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 MAPK8 4475/4885MEN1 3428/4885KMT2A 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.